BACKGROUND: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT. MATERIALS AND METHODS: Four hundred and seventy-six patients <60 years old with newly diagnosed CD20+ DLBCL were randomised to induction with ACE or ACVBP. Three hundred and thirty responders received HDT followed by ASCT. After ASCT, 269 patients were re-randomised to receive either maintenance rituximab or observation alone. Randomisation was stratified by the quality of response to ASCT. The primary end point of this study was event-free survival (EFS). RESULTS: At a median of 4 years' follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. CONCLUSION: The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months' follow-up.
RCT Entities:
BACKGROUND: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT. MATERIALS AND METHODS: Four hundred and seventy-six patients <60 years old with newly diagnosed CD20+ DLBCL were randomised to induction with ACE or ACVBP. Three hundred and thirty responders received HDT followed by ASCT. After ASCT, 269 patients were re-randomised to receive either maintenance rituximab or observation alone. Randomisation was stratified by the quality of response to ASCT. The primary end point of this study was event-free survival (EFS). RESULTS: At a median of 4 years' follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. CONCLUSION: The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months' follow-up.
Authors: Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass Journal: J Clin Oncol Date: 2012-10-22 Impact factor: 44.544
Authors: Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil Journal: Haematologica Date: 2015-04-24 Impact factor: 9.941
Authors: Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn Journal: Biol Blood Marrow Transplant Date: 2013-03-22 Impact factor: 5.742
Authors: C P Escalante; Y C Chang; K Liao; T Rouleau; J Halm; P Bossi; S Bhadriraju; N Brito-Dellan; S Sahai; S W Yusuf; A Zalpour; L S Elting Journal: Support Care Cancer Date: 2016-06-25 Impact factor: 3.603